JPRN-UMIN000000492已完成未知
Concurrent Treatment of Cardiovascular Disease in Peritoneal Dialysis (PD) patients. Multi-center Randomized Clinical Study with Aldosterone blockade (spironolactone) and Angiotensin Receptor Blocker (ARB) or Angiotensin-Converting-Enzyme Inhibitor (ACEI). - MCS/AA
agoya University0 个研究点目标入组 160 人开始时间: 2006年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Should be excluded even if one of them would be positive; Patients under 18, older than 80. Patients with anemia whose Hb is less than 9 g/dl. Patients treated for more than 5 years after initiation of dialysis. Patients with heart failure of NYHA III, IV. Patients with pregnancy or the suspected. Patients treated with acid-base fluid dialysis.
研究者
相似试验
尚未招募
不适用
Cohort Study on Treatment of Cardiovascular Diseases with Traditional Chinese MedicineCardiovascular DiseasesITMCTR2200005811Tianjin University of Traditional Chinese Medicine
已完成
不适用
Cardiac- and vascular disease (-abnormalities) as underlying cause of premature birth.premature birth100103941001027310003216NL-OMON39237Academisch Medisch Centrum300
招募中
3 期
ong term impact of RAS inhibition on cardio-renal outcomes: a comparative trial of angiotensin converting enzyme inhibitors, angiotensin receptor blockers or combined therapy with both agents in patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.Cardiovascular - Normal development and function of the cardiovascular systemMetabolic and Endocrine - DiabetesACTRN12607000333415Consorzio Mario Negri Sud2,100
进行中（未招募）
1 期
Treatment of heart and blood vessel disease (cardiovascular disease) with low dose blood thinner (low dose rivaroxaban) in people with advanced kidney disease or receiving dialysis (advanced chronic kidney disease).Improvement of cardiovascular outcomes in patients with advancedchronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.CTIS2024-512483-59-00The George Institute For Global Health2,000
尚未招募
不适用
Cardiovascular disease manifestations in COVID-19 patientsCTRI/2021/06/034065Dr Swati Datta